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Background: DsbA enzymes assemble bacterial virulence factors and are targets for an entirely new drug class.
Results: Proteus mirabilis DsbA was characterized and its structure determined with a peptide bound non-covalently at the
active site.
Conclusion: The structure provides an important basis for future inhibitor design.
Significance: New drugs to treat superbugs are urgently needed. DsbA inhibitors could have antivirulence activity against
bacterial pathogens.
The disulfide bond forming DsbA enzymes and their DsbB
interaction partners are attractive targets for development of
antivirulence drugs because both are essential for virulence fac-
tor assembly inGram-negative pathogens. Here we characterize
PmDsbA from Proteus mirabilis, a bacterial pathogen increas-
ingly associated with multidrug resistance. PmDsbA exhibits
the characteristic properties of a DsbA, including an oxidizing
potential, destabilizing disulfide, acidic active site cysteine,
and dithiol oxidase catalytic activity. We evaluated a peptide,
PWATCDS, derived from the partner proteinDsbB and showed
by thermal shift and isothermal titration calorimetry that it
binds to PmDsbA. The crystal structures of PmDsbA, and the
active site variant PmDsbAC30S were determined to high reso-
lution. Analysis of these structures allows categorization of
PmDsbA into the DsbA class exemplified by the archetypal Esche-
richia coli DsbA enzyme. We also present a crystal structure of
PmDsbAC30S incomplexwith thepeptidePWATCDS.Thestruc-
ture shows that the peptide binds non-covalently to the active site
CXXC motif, the cis-Pro loop, and the hydrophobic groove adja-
cent to the active site of the enzyme. This high-resolution struc-
tural data provides a critical advance for future structure-based
design of non-covalent peptidomimetic inhibitors. Such inhibitors
would represent an entirely new antibacterial class that work by
switching off the DSB virulence assemblymachinery.
Proteus mirabilis is a significant Gram-negative extra-intes-
tinal human pathogen that belongs to the Enterobacteriaceae
family, which also includes other important pathogens such as
Escherichia coli, Klebsiella pneumoniae, and Enterobacter clo-
acae. Together, the Enterobacteriaceae account for the vast
majority of community-acquired and nosocomial urinary tract
infections (1, 2). P. mirabilis is a frequent cause of both compli-
cated and catheter-associated urinary tract infections (3, 4).
Multidrug-resistant strains of clinical pathogenic P. mirabilis
have been reported for several decades (1). For example, clinical
isolates of P. mirabilis resistant to streptomycin, tetracycline,
kanamycin, chloramphenicol, and polymyxin B were described
in the 1960s (5, 6) and since then reports of antibiotic resistance
have increased (7–16).
DsbA enzymes from Gram-negative bacteria are targets for
the development of anti-virulence drugs that could represent
an entirely new class of antimicrobial agents (17, 18). Drugs that
target bacterial virulence couldminimize the selective pressure
that generates antibiotic resistance and simultaneously pre-
serve the endogenous host microbiome (19). DsbA is a key tar-
get for such drugs because it is essential for the correct folding
or assembly ofmultiple virulence factors, including toxins, fim-
brial adhesins, flagella, and type II and type III secretion systems
(17). The mutation of dsbA results in the attenuation of viru-
lence factor production inmultiple pathogens (17), some exam-
ples, include P. mirabilis (20), uropathogenic E. coli (21), and
Burkholderia pseudomallei (21, 22), Vibrio cholerae (23), Shi-
gella flexneri (24), and Salmonella enterica serovar Typhimu-
rium (25).
DsbAenzymes are thioredoxin-fold proteins (26) localized to
the periplasm of Gram-negative bacteria where they catalyze
oxidative folding (27). This reaction involves the transfer of a
disulfide bond from the active site 30CXXC33 motif of DsbA to
cysteine thiols in newly translocated proteins (28). Through
this disulfide-exchange reaction, the active site cysteines of
DsbA become reduced. The enzymatic cycle is completed
through oxidation of DsbA by the inner membrane partner
The atomic coordinates and structure factors (codes 4OCE, 4OCF, and 4OD7)
have been deposited in the Protein Data Bank (http://wwpdb.org/).
1 Both authors contributed equally to this article.
2 Supported throughanAustralianResearchCouncil Australian Laureate Fellow-
ship FL0992138 to J. L. M.
3 Supported by an Australian Research Council Future Fellowship FT100100662.
4 Supported by National Health and Medical Research Council Senior Princi-
pal Research Fellowship 1027369.
5 Supported by Australian Research Council Australian Laureate Fellowship
FL0992138 and Honorary National Health and Medical Research Council
Research Fellowship 455829. To whom correspondence should be
addressed. E-mail: j.martin@imb.uq.edu.au.
THE JOURNAL OF BIOLOGICAL CHEMISTRY VOL. 289, NO. 28, pp. 19810–19822, July 11, 2014
© 2014 by The American Society for Biochemistry and Molecular Biology, Inc. Published in the U.S.A.
19810 JOURNAL OF BIOLOGICAL CHEMISTRY VOLUME 289•NUMBER 28•JULY 11, 2014
 at UQ Library on October 4, 2016
http://w
w
w
.jbc.org/
D
ow
nloaded from
 
protein, DsbB (29). DsbA from E. coli (EcDsbA) is a highly pro-
miscuous enzyme that catalyzes disulfide bond formation in
many cysteine-containing proteins (28). In contrast, EcDsbB
has a very strict binding specificity for EcDsbA (29). The inter-
action between EcDsbA and EcDsbB involves the formation of
a mixed disulfide between Cys30 of the 30CXXC33 motif of
EcDsbA and Cys104 of EcDsbB in the P2 periplasmic loop,
which has the sequence 98PSPFATCDF106 (30). The crystal
structure of the complex between EcDsbA and EcDsbB also
revealed non-covalent binding of EcDsbB P2 loop residues to
the EcDsbA hydrophobic groove (30). The P2 periplasmic loop
sequence of P. mirabilis DsbB (PmDsbB) is identical to that of
EcDsbB, suggesting a similar interaction occurs between
PmDsbA and PmDsbB.
Here we characterize PmDsbA from P. mirabilis, which
shares 59% sequence identity with EcDsbA, and confirm its
activity as a DsbA enzyme.We demonstrate that the heptapep-
tide PWATCDS, derived from the DsbB P2 loop sequence,
binds to wild type PmDsbA and to a C30S active site variant
(PmDsbAC30S).We report three high-resolution crystal struc-
tures including the PmDsbAC30SPWATCDS complex, which
represents to our knowledge the first reported example of a
peptide bound non-covalently to a DsbA structure. This non-
covalent complex provides the critical starting point for the
design of non-covalent drugs that act as anti-virulence agents
targeting Enterobacteriaceae DsbAs.
EXPERIMENTAL PROCEDURES
Protein Production and Molecular Biology—Codon-opti-
mized wild type P. mirabilis dsbA (GenBank accession num-
ber CAR45574), lacking the sequence coding for the predicted
signal peptide (amino acids 1–19), was cloned into a modified
pMCSG7 (31) vector using ligation-independent cloning. The
cytoplasmic expressed PmDsbA contained an N-terminal
His6 affinity tag followed by a linker region including a
tobacco etch virus (TEV)6 protease cleavage site. The
PmDsbAC30S variant was generated from the wild type con-
struct using QuikChange (Agilent Technologies). The fol-
lowing primers were used to introduce the point mutation,
forward, GAATTTTTCTCATTTTATTCTCCGCATTGT-
TACC and reverse, GGTAACAATGCGGAGAATAAAATG-
AGAAAAATTC. Transformed BL21(DE3)pLys cells contain-
ing plasmids for either PmDsbA or PmDsbAC30S were grown
(1 liter) at 30 °C in 2.5-liter baffled shaker flasks for 16–20 h
using autoinduction media (32). Cells were resuspended in 25
mM Tris, 150 mM NaCl (10 g of cells/100 ml of buffer), and
protease inhibitor mixture (diluted 1 in 1000 into the lysate)
(BioPioneer Inc., SanDiego, CA) andDNase (1300 units/100ml
of lysate) (Roche Applied Science) were added. Lysis was per-
formed in a Cell Disruptor (TS-Series, Constant Systems LTD.,
UK) applying a single run with a constant pressure of 25 Kpsi.
Cell debris was removed by centrifugation (18,500 rpm, 30min,
4 °C, rotor JM-25.5, Beckman Coulter, Brea, CA). The proteins
were further purified by immobilized metal ion affinity chro-
matography using 12 ml/1-liter cells of equilibrated Talon
(Clontech) and eluted with 25 mM Tris, 150 mM NaCl, 200 mM
imidazole after incubation of 30 min at room temperature.
Total protein was determined at 280 nm with a NanoDropTM
2000c (Thermo Fisher Scientific). The His6 affinity tag was
removed by TEV cleavage using a 50:1 (w/w) ratio (protein/
TEV-protease) incubated in a 50-ml Falcon tube including 1
mM -mercaptoethanol for 2 h on a rotary mixer at room tem-
perature. After cleavage, the PmDsbA proteins had an addi-
tional two non-native residues (Ser2–Asn1) at the N termi-
nus. To remove imidazole, the mixture was rapidly buffer
exchanged into 25 mM Tris, 150 mM NaCl using a Sephadex
G-25 fine 16/60 column connected to an ÄKTA system (GE
Healthcare). The His6-tagged TEV protease was removed by
reverse metal ion affinity chromatography using Talon resin
(0.5 ml of resin/2 mg of TEV protease) (Clontech, Australia)
and the PmDsbA proteins were recovered in the flow through.
The final step of purification was performed using a Superdex
S75 gel-filtration column (GE Healthcare). Peak fractions were
then combined and the protein was oxidized using copper(II)/
1,10-phenanthroline at 1.7 mM final concentration or reduced
usingDTT at25molar excess. To remove oxidizing or reduc-
ing agent, the mixture was then buffer-exchanged into 10 mM
HEPES pH 7.4 using a Sephadex G-25 fine 16/60 column.
Finally, the protein was concentrated to 100 mg/ml using Ami-
con Ultra filter devices with a 10-kDa cutoff (Millipore). Yield
was generally 120–150 mg/liter of culture. Protein quality was
assessed by SDS-PAGE (NuPAGE system, 4–12% BisTris gel,
Invitrogen, Australia). Molar protein concentrations were
determined from calculated extinction coefficients derived
from ProtParam (33).
Purified EcDsbA (GenBank accession number CAA56736)
and EcDsbC (GenBank accession number AAA83074), lacking
the periplasmic leader signal were expressed and purified as
described above for PmDsbA. Yields were generally 120 and 80
mg/liter of culture, respectively.E. colimembrane extracts con-
taining over-expressed EcDsbB (GenBank accession number
AAC74269) were prepared as described previously (34), and
resuspended in PBS buffer containing 10% glycerol.
EcDsbA Complementation—E. coli dsbA (JCB817) and
dsbA/dsbB (JCB818) non-motile strainswere used formotil-
ity assays as described previously (35). The gene sequence cod-
ing for mature PmDsbA (lacking the periplasmic signal
sequence) was cloned into pBAD33 under an arabinose-induc-
ible promoterwith anN-terminal EcDsbA signal sequence (36).
As a positive control, EcDsbA was expressed within the same
pBAD33 vector background. 2 106 non-motile E. coli dsbA
(JCB817) anddsbA/dsbB (JCB818) double-mutant (JCB818)
(27) cells harboring pBAD33(EcDsbA) or pBAD33(PmDsbA)
were spotted onto the center of a soft M63 minimal agar plate
containing 40 mg/ml of each amino acid (except L-cysteine) in
the absence or presence of 0.1% arabinose (negative control).
Plates were incubated at 37 °C and cell motility was monitored
after 4–5 h using aMolecular ImagerGel DocTM system from
Bio-Rad. Complementation experiments were performed as
biological triplicates.
6 The abbreviations used are: TEV, tobacco etch virus; BisTris, 2-[bis(2-hy-
droxyethyl)amino]-2-(hydroxymethyl)propane-1,3-diol; HbtU, O-benzo-
triazole-N,N,N,N-tetramethyluroniumhexafluorophosphate; ITC, isother-
mal titration calorimetry; PDB, Protein Data Bank; r.m.s., rootmean square.
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Cysteine Thiol Oxidation Assay—A synthetic peptide sub-
strate of EcDsbA (CQQGFDGTQNSCK) with a europium
1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid group
amide coupled to the N terminus and amethylcoumarin amide
coupled to the -amino group of the C-terminal lysine was pur-
chased from AnaSpec (Fremont, CA) and prepared as previ-
ously reported (37).
Assays were performed using a Synergy H1 multimode plate
reader (BioTek) as described previously (38). In brief, fluores-
cence (excitation   340 nm and emission   615 nm) cor-
responding to disulfide formation in the substrate peptide was
measured in a white 384-well plate (PerkinElmer Life Sciences
OptiPlate-384, number 6007290) in 50 mM MES, 50 mM NaCl,
and 2 mM EDTA at pH 5.5 buffer. The total reaction volume in
each well was 50 l, containing 40, 80, or 160 nM PmDsbA or
EcDsbA, 1.6 M EcDsbB membrane, and 8 M peptide sub-
strate (added last to initiate the reaction). Controls used were:
PmDsbA or EcDsbA buffer substrate (no DsbB); EcDsbB
buffer  substrate (no DsbA); buffer  substrate (no DsbA or
DsbB); andno components (fluorescence backgroundof the plate,
which was subtracted from all othermeasurements). Three inde-
pendent experiments (biological replicates) were performed,
using three technical replicates for each measurement. The
reaction rate was estimated by calculating the increase in fluo-
rescence over the first 8min of reaction. The fluorescence rates
were plotted including the standard deviation calculated from
the three biological replicates.
Thermal Stability of PmDsbA—Temperature-induced unfold-
ing of native PmDsbA was recorded by UV circular dichroism as
previously reported for other DsbA enzymes (39) using a Jasco
J-810 spectropolarimeter (Jasco). The initial redox state of
PmDsbA was confirmed by Ellman’s assay (40). The maximum
difference in CD signal was determined by subtraction of the
CD spectra of the folded protein (25 °C) from the unfolded
(95 °C) protein, for the oxidized and the reduced forms of the
protein. Unfolding of oxidized PmDsbA (210 nm) and reduced
PmDsbA (213 nm) was monitored in a 1-mm quartz cuvette
using a heating rate of 1 °C/min from 25 to 95 °C. Measure-
ments were carried out using 10M protein in a buffer contain-
ing 100 mM NaH2PO4/Na2HPO4, 1 mM EDTA, pH 7.0. To
ensure PmDsbA remained reduced throughout the entire
measurement, reduced samples contained 0.75 mM DTT. Data
were fitted to a two-state unfolding model and errors were cal-
culated using Prism 6 (GraphPad) as described previously (41).
Redox Properties of PmDsbA—The standard redox potential
of PmDsbAwasmeasured utilizing the intrinsic fluorescence of
tryptophan residues in PmDsbA, similar to themethod used for
EcDsbA (42). In brief, oxidized PmDsbA was equilibrated for
3 h at 25 °C in degassed 100mMNaH2PO4/Na2HPO4, pH 7.0, 1
mMEDTA, containing 1mMoxidized glutathione (GSSG) and a
range of reduced glutathione (GSH) concentrations (0–2000
M). 200 l of PmDsbA from each redox condition was dis-
pensed into a 96-well plate (TPP AG, Switzerland, number
92096) and tryptophan fluorescence was measured (excitation
wavelength 280 nm, emission 332 nm) using a Synergy H1
microplate reader and Gen5 2.0 software (Biotek). Data were
analyzed in Prism 6 (GraphPad) and the redox potential was
calculated as described previously for EcDsbA (42).
Determination of Cys30 pKa—Absorbance at 240 nm of the
catalytic thiolate anion is pH-dependent allowing the equilib-
rium between protonated and deprotonated Cys30 to be mea-
sured (43) using a UV-visible spectrophotometer (CARY 50,
Agilent Technologies). Absorbance at 240 and 280 nm were
measured over pHvalues starting at 6.5 and decreasing to 2.0, in
0.25 pH unit increments. Samples contained either oxidized or
reduced PmDsbA (40 M) in composite buffer (10 mM Tris, 10
mM sodium citrate, 10 mM K2HPO4, 10 mM KH2PO4, 200 mM
KCl, and 1 mM EDTA) at 22 °C. The pKa value was calculated
from the fitted curves using the Henderson Hasselbalch equa-
tion (pH  pKa  log ([A240/A280]red/[A240/A280]ox)). Average
and mean S.D. from triplicate measurements are plotted.
Disulfide Reductase Activity—DsbA enzymes can reduce the
intermolecular disulfide bonds between insulin chains A and B
under mild reducing conditions (27). Disulfide bond reduction
of insulin can be followed spectrophotometrically at   650
nm (A650 nm). The A650 nm value gives a measure of turbidity,
which occurs as a result of the increase in production of insol-
uble B chain of insulin (44). Samples were prepared in 1-cm
cuvettes containing 10 M protein (PmDsbA, EcDsbA, or
EcDsbC), 0.33mMDTT, and 2mMEDTA in 100mMNaH2PO4/
Na2HPO4, pH 7.0. Catalysis was initiated by the addition of
0.131 mM insulin (I0516, Sigma) to the mixture. The assay was
repeated three times and the mean S.D. of the measurement
at each time point was calculated.
Peptide Synthesis—Peptides were synthesized using solid-
phase peptide synthesis on rink-amide (4-methyl)benzhydryl-
amine resin (ChemImpex International, Wood Dale, IL) with a
loading of 0.65 mmol/g. De-protection of the resin and amino
acids was performed using an 80:20 (v/v) mixture of dimethyl-
formamide/piperidine (Rci Labscan, Bangkok Thailand/Aus-
pep, Australia) for 2  5 min. L-Amino acids (ChemImpex
International) were activated using 4 resin equivalents (eq) and
4 eq of HbtU (O-benzotriazole-N,N,N,N-tetramethyluro-
nium hexafluorophosphate, ChemImpex International) (500
mM) and 5 eq of N,N-diisopropylethylamine (Auspep, Austra-
lia) for 5 min before coupling to the de-protected resin for 60
min. After the final coupling, all peptides were acetylated at the
N terminus using 4 eq of acetic acid (ChemSupply, Australia), 4
eq of HbtU, and 5 eq ofN,N-diisopropylethylamine for 30 min.
Cleaving was executed using a 95:2.5:1.25:1.25 (v/v) mixture of
trifluoroacetic acid (TFA)/ethanedithiol/triisopropylsilane/
water (H2O) (chemicals fromSigma). Cleaved peptides resulted
in an amidated C terminus from the resin rink-amide and dried
using N2 gas, washed with diethyl ether (DEE, Ajax Finechem,
Sydney Australia), and dissolved in a 80:20 (v/v) mixture of
acetonitrile/H2O (RCI Labscan, Bangkok, Thailand) before
purification on HPLC. Purification was executed on a C18 col-
umn (Phenomenex, Torrance CA) using a gradient from 20 to
80% of acetonitrile and TFA 0.1%. Fractions were analyzed by
mass spectrometry (Waters Micromass LCT,Milford, CT) and
the purified peptide was lyophilized using a freeze drier (Christ,
Osterode am Harz, Germany).
Peptide-induced Thermal Shift Measurements—25 M
PmDsbA in phosphate-buffered saline (PBS), pH 7.4, was incu-
bated with peptide PWATCDS at concentrations ranging from
125 M to 4 mM for 1 h. Then Sypro Orange (S-6650, Invitro-
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gen) was added to a 5 final concentration (stock concentra-
tion5000). Controls contained either no peptide, noDsbA, or
the dye alone. Measurements were conducted in a white 384-
well plate (Perkin Elmer OptiPlate-384, number 6007290) with
5 replicates. Fluorescence emission from SyproOrange binding
to unfolded protein was measured following a temperature
time course increasing from 25 to 95 °C (heat rate 0.05 °C/s)
using a VIAA7 Real-time PCR system (Invitrogen) with a  
585  15 nm wavelength filter. Raw data were analyzed using
Prism 6 (GraphPad). Fluorescence emission was fitted to a clas-
sic Boltzmann sigmoidal curve, and the inflection point was
used as the melting temperature, Tm. To determine Tm (the
shift in melting temperature in the presence of peptide), the
Tm value for the wild type protein was subtracted from
the Tm value for PmDsbA-PWATCDS and the Tm value for
the variant PmDsbAC30S was subtracted from the Tm value
for PmDsbAC30S-PWATCDS. Tm values are presented as
the mean S.D. from 5 replicates. A significant Tm is con-
sidered to be greater than two times the S.D. of the Tm value
for the protein in the absence of ligand (45).
Isothermal Titration Calorimetry—Evaluation of affinity and
thermodynamicsof bindingbetweenPWATCDSandPmDsbAor
PmDsbAC30S were assessed by isothermal titration calorimetry
(ITC)using anAuto-iTC200 instrument (MicroCalTM,GEHealth-
care). The sample cell was loaded with 200 l of purified protein
(oxidized PmDsbA or untreated PmDsbAC30S) at 100 M con-
centration in 25 mM HEPES, pH 7.4, 50 mM NaCl, 0.8% dimethyl
sulfoxide (ITC buffer). The syringe was filled with purified pep-
tide PWATCDS in ITC buffer at a concentration of 4 mM.
Titrations were conducted at 25 °C using 19 consecutive injec-
tions of 2 l each delayed by 180 s with a stirring speed of 1000
rpm. In every experiment an initial 0.5 l of peptide was
injected to avoid slow leakage of titrant and this data point was
discarded for binding analysis. As a control for background
noise, titration of PWATCDS into a solution containing ITC
buffer only was performed. The association constant (Ka 
1/Kd), free energy (G), and enthalpy change (H) were calcu-
lated by fitting the data to a single-site binding model using the
MicroCalOrigin software (Origin 7.0 SR4 version 7.0552) and
correcting peptide concentrations to adjust the stoichiometry
parameter close to 1.0. Entropy change (S) was deduced from
the standard free energy equationGHTS. Parameters
reported include the mean  S.D. across three replicates. The
calculated c-value for these measurements is 12.
Crystallization, Structure Determination, and Structural
Analysis—Crystallization screening was performed at the Uni-
versity of Queensland ROCX diffraction facility. Protein crys-
tallization trials were performed in 96-well plates using the
hanging drop vapor diffusion method at 8 or 20 °C. In general,
purified protein (200 nl) wasmixedwith crystallization solution
(200 nl) using a Mosquito crystallization robot (TTP Labtech,
UK), and trays were incubated and imaged in a RockImager
1000 (Formulatrix). Wild type PmDsbA was crystallized by
mixing a 1:3.3 molar ratio of the proteinpeptide complex
PmDsbAPSPWATCDF (3 mM protein, 10 mM peptide, 2%
dimethyl sulfoxide incubatedon ice for1h)with0.5l of15%PEG
3350 and 0.4 M sodiummalonate, pH 5.0, and incubating the drop
over the same solution at 20 °C. The presence of the peptide per-
mitted crystallization but no densitywas evident for the peptide in
the phased data; the final refined structure from this condition is
referred to as native PmDsbA. Crystals were harvested in cryo
solution (25%PEG3350, 0.4M sodiummalonate, pH5.0, 20%PEG
400) and immediately flash frozen in liquid nitrogen.
PmDsbAC30S crystals appeared overnight at 8 °C in
0.2 M KSCN, 23% PEG 3350 using a 1:10 molar ratio of the
proteinpeptide complex (1.5mMprotein and 15mMPWATCDS,
final concentrations of both, incubated on ice for 1 h); again the
presence of the peptide permitted crystallization but there was
no evidence of peptide binding in the electron density maps.
The cryo solution used was 0.2 M KSCN, 25% PEG 3350, and
20% PEG 400. The structure of the protein derived from this
condition is referred to as PmDsbAC30S.
PmDsbAC30SPWATCDS co-crystals grew at 20 °C using a
1:10 molar ratio of the proteinpeptide complex (3 mM protein,
30mMpeptide, final concentrations of both), with the two com-
ponents incubated on ice for 1 h prior to crystallization. The
proteinpeptide solution was then mixed with an equal volume
of crystallization solution, which contained 0.2 M KSCN, 22%
PEG 3350, 0.2 M non-detergent sulfobetaine (NDSB-221). Dif-
ferences in crystallization conditions in comparison to the
PmDsbAC30S crystals that did not yield bound peptide
included higher concentrations of protein and peptide (but the
same molar ratio), the use of NDSB-221 as an additive and an
incubation temperature of 20 °C (rather than 8 °C). Crystals
were flash frozen in cryo solution consisting of 0.3 M KSCN,
30% PEG 3350, and 20% PEG 400.
Diffraction data for all three crystal structures were mea-
sured at the Australian Synchrotron MX2 beamline at a wave-
length of 0.9537 Å, and recorded with an ADSCQuantum 315r
detector controlled by BLU-ICE (46). Reflections were indexed
and integrated in Mosflm (47) or XDS (48), analyzed in Point-
less (49), and scaled in SCALA (49) from the CCP4 suite (50).
Phases for PmDsbA were obtained by molecular replacement
using PHASER (51) with EcDsbA as a template (PDB code
1FVK, sequence identity 59%). PmDsbAC30SPWATCDSwere
solved using the wild type PmDsbA structure as the template.
Initial electron density maps from PHASER were improved by
cycles of iterative refitting of the model using the program
COOT (52) and PHENIX.refine (53). The refinement of the
complex structure was stalled at R-factor/R-free: 30/33%. Phe-
nix.xtriage analysis indicated that the diffraction data were
twinned with a twinning fraction of 0.49. The twin target
function implemented in PHENIX was applied in further
refinement cycles with the twinning operator hk, k, l.
The final R-factor/R-free was 17.2/19.9%. For PmDsbAC30S
PWATCDS, the density corresponding to the bound peptide
was modeled for all seven residues including N-terminal acety-
lation and C-terminal amidation. In addition, a malonate anion
was modeled into the crystal structure of PmDsbA and four
SCN molecules were modeled into the PmDsbAC30S
PWATCDS crystal structure with one pair in each protomers A
and C. One thiocyanate molecule is buried between 1 and 2
of protomers A/C, whereas the secondmolecule binds between
Pro andPmDsbAC30Shelix1, possibly forming aweak hydro-
gen bond with the Pro backbone carbonyl (distance N:O 3.4
Å). Thiocyanate molecules do not appear to influence peptide
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binding, because the peptide binding site and conformation is
identical in protomer B, which lacks a bound thiocyanate.
Data processing and refinement statistics for all three crystal
structures are provided in Table 1. Molecular figures were gen-
erated using PyMOL (ThePyMOLMolecularGraphics System,
version 1.6.0.0 Schrödinger, LLC) and figures of the electro-
static potential were generated using APBS (54). r.m.s. devia-
tion calculations and structural alignments were conducted in
PyMOL and FATCAT (55). Interaction analyses were con-
ducted with the program COOT (52) and the PDBePISA (56)
and Cocomaps servers (57).
RESULTS
PmDsbA Catalyzes Disulfide Formation in Vitro and in Vivo—
DsbA enzymes catalyze oxidative folding, or the introduction of
disulfide bonds into proteins. To assess whether PmDsbA has
dithiol oxidase activityweassessed its activity in an in vitropeptide
oxidation assay. A europium-labeled peptide (CQQGFDGTQN-
SCK) fluoresces when the two cysteines are oxidized, but not
when the cysteines are reduced (37). We found that PmDsbA,
like EcDsbA, catalyzed peptide thiol oxidation as evident by an
increase in the fluorescent signal over time (Fig. 1A). The fluo-
rescence rate increased with increasing concentrations of
PmDsbA and EcDsbA (Fig. 1A). PmDsbA catalysis was a little
slower than that of EcDsbAat the same enzyme concentrations.
This slightly reduced activity may reflect the use of a peptide
derived fromanEcDsbA substrate.Nonetheless, the results estab-
lish that PmDsbA catalyzes dithiol oxidation in amodel substrate.
We also assessed the ability of PmDsbA to complement
EcDsbA in vivo. E. coli strains deficient in the P-ring protein
FlgI fail to assemble functional flagella (58). Moreover,
E. coli strains lacking EcDsbA, EcDsbB, or both, have the
same phenotype (59) because FlgI requires a disulfide bond
to function. The non-motile strains E. coli dsbA (JCB817)
and dsbA/dsbB (JCB818) were therefore used for in vivo
DsbA complementation experiments. When EcDsbA or
PmDsbA were expressed in JCB817 following arabinose
induction, full rescue of motility was observed in JCB817
(Fig. 1B). However cells from the double knock-out (JCB818)
remained non-motile for both PmDsbA and EcDsbA. These
results demonstrate that PmDsbA can replace EcDsbA func-
tionally in vivo in the context of flagella assembly. Because
EcDsbB was also essential for complementation in this
experiment, the results confirm that PmDsbA and EcDsbB
can form a functionally competent system. This was
expected because the P2 loop sequence from PmDsbB is
identical to that of EcDsbB. Furthermore, the P. mirabilis
FlgI homologue shares 74% sequence identity with EcFlgI
including two conserved cysteine residues.
PmDsbA Shares the Same Characteristic Redox Properties as
EcDsbA—DsbA enzymes exhibit unique properties that con-
tribute to their ability to catalyze disulfide bond formation (28,
TABLE 1
X-ray data collection and refinement statistics
Data collection PmDsbA (4OCE)
PmDsbAC30S
(4OCF)
PmDsbAC30S  PWATCDS
(4OD7)
Wavelength (Å) 0.95369 0.95369 0.95370
Resolution range (Å) 42.64–1.77 57.22–1.98 64.13–1.60
Highest resolution shell (Å) 1.86–1.77 2.09–1.98 1.68–1.60
Space group P 43212 P21 P32
Unit cell dimensions
a (Å) 37.8 37.9 74.06
b (Å) 37.8 80.2 74.06
c (Å) 298.4 114.4 93.27
, ,  (°) 90, 90, 90 90, 91, 90 90, 90, 120
Total reflections 303398 176891 839517
Unique reflections 22817 47865 74969
Multiplicity 13.3 (13.6)a 3.7 (3.6)a 11.2 (10.2)a
Completeness (%) 100 (100) 99.7 (98.9) 98.6 (93.9)
Mean 	I
/	I
 16.1 (4.8) 14.3 (8.4) 16.3 (2.4)
Rmergea 0.127 (0.587) 0.073 (0.155) 0.080 (0.973)
Rp.i.m. 0.035 (0.157) 0.044 (0.095) 0.026 (0.327)
Refinement statistics
Rfree (%) 16.9 (21.9) 21.1 (24.0) 19.9 (29.2)
Rwork (%) 14.8 (17.3) 15.2 (15.2) 17.2 (30.3)
Unique reflections 22686 47846 74969
Number of non-H atoms
Protein 1492 5841 4506
Water 268 810 542
Protein residues 189 749 561
r.m.s. deviation bond
Lengths (Å) 0.009 0.012 0.017
Angles (°) 1.152 1.240 1.555
Ramachandran
Favored (%) 98.4 98.5 98.9
Outliers (%) 0 0 0
Average B-factor (Å2) 14.6 12.8 25.7
Wilson B-factor (Å2) 16.0 10.3 22.1
Molprobityb
Clashscore (percentile) 1.03 [100th, (839)] 2.32 [100th, (714)] 4.25 [97th, (699)]
Score (percentile) 0.80 [100th, (11193)] 1.01 [100th, (12309)] 1.21 [98th, (6780)]
a The values in parentheses refer to the highest resolution shell.
b 100th Molprobity (74) percentile is the best among the structures of comparable resolution. The percentile and the number of structures included in the comparison (N)
are given in parentheses within the square bracket.
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60). We next established whether these characteristics are
shared by PmDsbA. First, we investigated the relative thermo-
stability of the oxidized and reduced forms of the enzyme. In
most DsbAs, the reduced form of the CXXC active site is
more stable than the oxidized form. For instance, the melt-
ing temperature of reduced EcDsbA is almost 10 K higher
than that of the oxidized form (39). Similarly, we found that
reduced PmDsbA (Tmred 348.4  0.1 K) is 10 K more stable
than oxidized PmDsbA (Tmox 338.4  0.2 K) (Fig. 1C).
DsbAs are also highly oxidizing. The redox potential of
EcDsbA is 122 mV (42) and the range of values reported for
other DsbAs varies from 80 mV for NmDsbA1 (37) to 163
mV for WpDsbA (41). Nevertheless, closely related (80%
sequence identity) homologues of EcDsbA such as SeDsbA and
KpDsbA have redox potential values very similar to that of
EcDsbA (126 and 116 mV, respectively). We determined
the redox potential of PmDsbA to be129mV (Fig. 1D), which
is consistent with those of other Enterobacteriaceae DsbAs.
The oxidizing nature of DsbA proteins is thought to be a
consequence of the highly acidic cysteine in the CXXC active
sitemotif. The pKa of 3.3 for this nucleophilic cysteineCys30 for
EcDsbA is unusually low for a cysteine (pKa 9.0) (61). Values
reported for other DsbAs vary from 3.0 (NmDsbA1) (62) to 5.1
(VcDsbA) (63).Wemeasured the pKa of the equivalent cysteine
in PmDsbA, bypH-dependent specific absorbance at240nm,
anddetermined thevalue tobe4.0 (Fig. 1E).Thus, thenucleophilic
FIGURE 1. Redox properties of PmDsbA. A, in vitro disulfide catalysis. Plot shows increase in fluorescence as a consequence of peptide disulfide formation
catalyzedbyEcDsbAor PmDsbA in thepresenceof EcDsbB.B, in vivodisulfide catalysis.dsbA knock-out ordsbA/Bdouble knock-out cells arenon-motile due
to their inability to fold FlgI. Expression of PmDsbAor EcDsbA restoresmotility indsbA, but not indsbA/B.C, thermalmelting curves of oxidized and reduced
PmDsbA shows that reduced PmDsbA (Tm
red 348.4 0.1 K) is more stable than its oxidized counterpart (Tm
ox 338.4 0.2 K). D,measurement of PmDsbA redox
potential. PmDsbA was equilibrated in glutathione (GSSG/GSH) redox buffers to measure the equilibrium constant Keq (187. 5 6M), which corresponds to
a redox potential of129mV. E, absorbance of the catalytic thiolate anion is pH-dependent and this property was used to determine that the pKa of PmDsbA
Cys30 is 4.0. F, disulfide reductase activity measured by following A650 nm. PmDsbA has activity similar to that of EcDsbA, and much lower than that of the
isomerase EcDsbC. For panels A and C–F, data are presented as mean S.D. from three biological replicates. The error bars for the DsbA-only and buffer-only
controls in panel A are essentially 0 as there was no increase in fluorescence over the period of the experiment.
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cysteine of PmDsbA, like that of other DsbAs, is likely to be in the
thiolate form at physiological pHwhen the enzyme is reduced.
Although DsbA proteins are dithiol oxidases they can cata-
lyze disulfide reduction in the presence of mild reducing agents
such as DTT. Typically, insulin is used as a substrate to study in
vitro disulfide bond reduction. The two chains of insulin are
linked by three disulfide bonds,which can be rapidly reduced by
disulfide reductases such as the disulfide isomerase EcDsbC.
This reduction leads to separation of the insulinA andB chains,
and precipitation of the insoluble B chain. Reduction can be
followed by measuring the increase in turbidity of the solution
over time. We found that PmDsbA is able to reduce the disul-
fide bonds of insulin as rapidly as EcDsbA (Fig. 1F), but more
slowly than the specialist reductant EcDsbC. In summary, the
redox properties of PmDsbA reported here place it in the same
class as EcDsbA and other Enterobacteriaceae DsbAs such as S.
entericaDsbA(SeDsbA)andK.pneumoniaeDsbA(KpDsbA) (18).
PWATCDS Binding to PmDsbA and PmDsbAC30S—We
were interested to understand how peptides interact with
PmDsbA, as the basis for future peptidomimetic inhibitor
development. The low resolution crystal structures and NMR
characterization of the EcDsbBEcDsbA complex revealed that
the EcDsbB periplasmic loop P2 forms a mixed disulfide with
the nucleophilic cysteine of EcDsbA and binds to a hydropho-
bic groove near the active site (29, 30, 64, 65). The peptide
sequence of the EcDsbBP2 loop 98PSPFATCDF106 is conserved
in PmDsbB (99PSPFATCDF107) suggesting that a similar inter-
action occurs between PmDsbA and PmDsbB. From the
sequence of this P2 loop peptide, we developed a shorter, mod-
ified peptide PWATCDS optimized for solubility, binding
affinity, and inhibition of EcDsbA.7 Briefly, alanine scanning,
peptide length scouting, and substitution of specific residues
showed that the peptide PWATCDShad a good affinity tomass
ratio for binding to EcDsbA.We hypothesized that this peptide
would also interact with PmDsbA, and therefore evaluated its
binding using thermal shift assay and ITC.
Tm values for PmDsbA andPmDsbAC30S (a variant inwhich
the nucleophilic cysteine was replaced by serine) were mea-
sured in the presence and absence of the peptide PWATCDS,
with varying peptide concentrations. For PmDsbA,Tm values of
2.0, 4.1, and 5.0 K were observed at peptide concentra-
tions of 1, 2, and 4mM, respectively, suggesting that PWATCDS
binds to PmDsbA. These data show that theTm shift continued
with increasing peptide concentration beyond saturation, as is
commonly observed in this assay (66). When the variant
PmDsbAC30S was used, thermal shifts (Tm  0.3 K) were
detectable at concentrations of PWATCDS ranging from 250 M
to 4 mM. However, the maximum Tm at 4 mM was significantly
lower than that at the sameconcentration forPmDsbA(Tm1.5
K, compared with 5.0 K, respectively) (Fig. 2A). This difference in
Tm suggests the possibility of different bindingmodes.
We also investigated the interaction using ITC. An exother-
mic reaction was observed when titrating PWATCDS into
PmDsbA (Fig. 2B). Analysis of the raw data using a 1:1 binding
model revealed a binding affinityKD of 8.3 0.4Mwith a high
enthalpic contribution (H  13.7  0.3 kcal/mol) and an
unfavorable entropy of binding (S  22.3  1.1 cal/mol/
deg). When PmDsbAC30S was used, there was no evidence of
PWATCDS binding by ITC under these same conditions (Fig.
2C). Clearly, the C30S mutation reduced the affinity of peptide
binding, as evidenced by both thermal shift and ITC. Neverthe-
less, wewere able to generate a crystal structure of this complex
as described below. These differing outcomes for the appar-
ently weak complex of PmDsbAC30SPWATCDS may be a
consequence of different experimental design (thermal shift
and crystallization used a 1-h preincubation of peptide with
PmDsbAC30S, ITC methodology does not allow this; ITC was
performed at 25 °C, whereas preincubation was done at 4 °C
7 W. Duprez, L. Premkumar, M. Halili, F. Lindahl, R. Reid, D. P. Fairlie, and J. L.
Martin, unpublished data.
FIGURE 2. Peptide PWATCDS interacts with PmDsbA. A, values of Tm upon addition of increasing PWATCDS peptide for PmDsbA and PmDsbAC30S. Data
are shown as mean  S.D. from 5 replicates. B, ITC data titrating PWATCDS into PmDsbA. The reaction was exothermic suggesting a dominant enthalpic
contribution to binding. C, ITC data titrating PWATDCS into PmDsbAC30S. Panels B and C show a representative example from three replicates.
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and crystallization at 20 °C) or different experimental condi-
tions (buffer, pH, and concentration of peptide as outlined
under “Experimental Procedures”).
Crystal Structure of PmDsbA—To investigate the different
binding modes further, we attempted to determine the crystal
structures of PmDsbA and PmDsbAC30S, in the presence of
the peptide PWATCDS.Wewere unable to generate a crystal of
a stable complex of PmDsbA with PWATCDS. However, crys-
tals of PmDsbA and PmDsbAC30S without peptide, and
PmDsbAC30S with peptide yielded high-resolution diffraction
data (PmDsbA, 1.77-Å resolution; PmDsbAC30S, 1.98-Å reso-
lution; and PmDsbAC30S-PWATCDS, 1.6-Å resolution).
PmDsbA crystallized in a tetragonal crystal system and was
solved (PDB code 4OCE) by molecular replacement using the
EcDsbA structure (PDB code 1FVK) as a template. One protein
chain is present in the asymmetric unit, and this has a typical
DsbA-like architecture, comprising a TRX core domain (1,
2,1,3,C-terminal region of6,4,5, and7), interrupted
by an -helical domain (2-5 and the N-terminal region of
6). This PmDsbA structure is structurally similar to other
Enterobacteriaciae DsbAs including EcDsbA (PDB code 1FVK
(67)), KpDsbA (PDB code 4MCU (18)), and SeDsbA (PDB code
3L9S (68)) (Fig. 3A). This is reflected in the r.m.s. deviation of
1.0–1.2 Å comparing 177 C atoms from equivalent positions
of these enzymes. Fig. 3B shows a structure-based sequence
alignment of PmDsbA with homologous DsbA proteins from
clinically relevant pathogens that share 59% sequence
identity. Sequences are highly conserved, especially at the
active site CPHC motif. Sequence identity translates into
overall structural similarity between DsbA proteins from
these pathogens.
The sequence and structure of the active site motif (CPHC)
and the cis-Pro loop are identical in these DsbA homologues.
However, helix 1 and the loops connecting 1 and 2, and 3
and 4 differ in their relative positions. Most importantly loop
L3 that connects 3 and helix 7 varies across the structures.
The EcDsbA L3 residues Asp167, Thr168, and Ser169 are posi-
tioned closer to the active site helix 1 than the equivalent
residues (Ala167, Lys168, and Ser169) in PmDsbA. This region is
relatively hydrophobic in both PmDsbA and EcDsbA, although
more basic in PmDsbA than in EcDsbA due to the presence of
Lys159 in the former and Gln160 in the latter. Overall these dif-
ferences in structure are relatively minor compared with the
structures of other DsbA proteins, such as Pseudomonas
aeruginosa DsbA (25% identity with PmDsbA, r.m.s. deviation
2.2 Å, 175 C, PDB code 3H93 (35)), and Wolbachia pipientis
DsbA1 (16% identity with PmDsbA, r.m.s. deviation 3.6 Å, 151
C, PDB code 3F4R (41)).
Crystal Structure Determination of PmDsbAC30S and
PmDsbAC30SPWATCDS—We solved the structure of the
active site mutant PmDsbAC30S (PDB code 4OCF). The
crystals grew in the presence of peptide, but no bound pep-
tide was evident in the electron density map. We therefore
used this structure of PmDsbAC30S to assess whether
replacement of Cys30 with Ser30 induced any structural
changes. The mutant crystallized in a monoclinic crystal sys-
tem containing 4 protomers in the asymmetric unit. The
structure was solved by molecular replacement using the
coordinates of PmDsbA described above. The average r.m.s.
deviation for comparison of the 6 combinations of the 4
protomers range from 0.3 to 0.7 Å for 177 equivalent C
atoms (residues 6–181).
PmDsbAC30S in complex with peptide PWATCDS crystal-
lized in a trigonal crystal system, containing 3 protomers in the
asymmetric unit. The complex was solved by molecular
replacement using PmDsbA (PDB code 4OD7) as the template.
All three protomers (A, B, and C) reveal strong electron density
corresponding to bound PWATCDS. The average r.m.s. devia-
tion for the 3 comparisons of the protomers in this crystal struc-
ture range from 0.4 to 0.6 Å for 177 equivalent C atoms
(residues 6–181). The r.m.s. deviation for comparison of
PmDsbAC30S with PmDsbAC30SPWATCDS range from 0.5
to 0.9 Å (177 C) for the 12 combinations. Similarly, compar-
ison of the wild type PmDsbA structure with PmDsbAC30S
and PmDsbAC30SPWATCDS gave r.m.s. deviation values
of 0.3–0.9 Å (177 C). This result indicates there is no major
reorganization of the PmDsbAC30S structure upon interac-
tion with PWATCDS. However, there is evidence of rigid
body shifts for helix 1 and side chain adjustments for resi-
dues on helix 1 (His32, Tyr34, Gln35, Phe36, Ser37) and flexible
loop 3 (Ile165 and Ser166) that together form part of the pep-
tide binding site.
Active Site Structure Is Conserved after Peptide Binding—A
comparison of the active site motifs (CPHC and CPHS) and
the Val150/Pro151 residues of the cis-Pro loop across all the
protomers in the PmDsbA, PmDsbAC30S, and PmDsbAC30S
PWATCDS crystal structures reveals a high degree of structural
conservation. The active site cysteines Cys30 and Cys33 in the
native PmDsbA structure were modeled as a mixture of oxi-
dized and reduced (ratio 0.7:0.3). In the oxidized state the two
sulfurs (Fig. 3C) are 2.2 Å apart, reflecting the typical length of a
covalent disulfide bond found in other oxidized DsbA struc-
tures (e.g.EcDsbA and SeDsbA, S-S distance 2.0Å) (26, 68). The
dithiol form of the cysteines is likely a consequence of radiation-
induced disulfide reduction. The distance between the dithiol sul-
furs is 3.4Å. In the PmDsbAC30S and PmDsbAC30SPWATCDS
structures, the distance between the hydroxyl oxygen of Ser30
and the sulfur atom of Cys33 varies between 3.3 and 3.5 Å (Fig.
3D). These distances are in agreement with those of other
reducedDsbA structures (e.g.KpDsbA 3.3–3.8 Å) (18). Overall,
there is no apparent change in the active site upon binding of
the peptide.
Peptide Binding Mode and Interaction with PmDsbAC30S—
The binding mode of the peptide (Fig. 4, A and B) is highly
conserved across the three protomers (r.m.s. deviation 0.1–0.2
Å over all 82 atoms). The electron density from this high-reso-
lution structure provides strong evidence for both the position
and conformation of the bound peptide (Fig. 4C). The binding
site for PWATCDS (residues 1 to 7) includes the hydrophobic
groove and the active site regions (CXXC and cis-Pro motif) of
the enzyme. As expected, the hydrophobic residues Pro1 and
Trp2 (italics indicate peptide residues) interact with the hydro-
phobic groove, and the C-terminal residues interact with the
cis-Pro region of the active site.
However, the observed bindingmodewas not entirely as pre-
dicted. On the basis of the EcDsbAEcDsbB covalent complex,
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Cys5 of the peptide should interact with PmDsbAC30S residue
30 (mutated fromCys to Ser). This was not the case. In all three
complexes in the asymmetric unit, Asp6 and not Cys5 interacts
with PmDsbAC30S Ser30 (Fig. 4D). The acidic side chain of
Asp6 is within hydrogen bond contact distance of Ser30 and
His32. Moreover, the backbone amide of Asp6 forms hydrogen
bonds with the backbone amide of Val149 of the PmDsbAC30S cis-
Pro loop (Fig. 4D).
Comparison of Peptide Binding Mode with DsbA-DsbB
Complexes—The EcDsbB P2 loop (sequence PSPFATCDF) and
the synthetic peptide we used (PWATCDS) share the same bind-
ing location on EcDsbA and PmDsbAC30S, respectively. The
EcDsbA-EcDsbB complex (3.7-Å resolution (30)), revealed
one possible hydrogen bond between P2 and the enzyme
(backbone oxygen of Arg148 of the EcDsbA cis-Pro loop with
the backbone nitrogen of EcDsbB Phe106). All other interac-
tions with the P2 loop, aside from the covalent disulfide, are
hydrophobic (28).
As indicated above, no interaction was observed between
Cys5 and Ser30 of PmDsbAC30S. Instead, hydrogen bond inter-
actions with Asp6 and hydrophobic interactions with Trp2
appear to dominate the PWATCDS binding mode. Residues
between these two anchor points, Cys5, Thr4, and Ala3, pro-
trude out of the binding site relative to the equivalent EcDsbB
loop residues (Fig. 4, E and F).
The r.m.s. deviation for comparison of PWATCDS with the
EcDsbB P2 loop conformation is relatively high (2.2 Å for 28
backbone atoms), because of the bulge in the peptide confor-
FIGURE 3. Crystal structure of PmDsbA and its comparison with close homologues. A, structural comparison of four closely related DsbA homologues,
PmDsbA (4OCE) in cyan, EcDsbA (1FVK protomer B) in white, KpDsbA (4MCU protomer E) in orange, and SeDsbA in green. Conserved structural regions are
annotated; the catalytic cysteines are shown as yellow spheres. B, structure based sequence alignment of EcDsbA (1FVK, chain A), SeDsbA (3L9S, chain A),
KpDsbA (4MCU, chain F), and PmDsbA (4OCE, chain A). Sequence identitywith EcDsbA is shownon the left, conserved residues are black, differing residues are
red. The TRX domain is highlighted in light gray, and the helical domain in dark gray. Red squaresmark the three loop regions L1/2/3. Amino acid conservation
code is shown beneath the sequences. The active site CXXC motif is highlighted in blue, and the cis-Pro region in green. Secondary structure elements are
indicatedabove the sequences. Residuesunderlined in EcDsbAbind to theEcDsbBP2 looppeptide (PISA server analysis).C, CXXCactive site of PmDsbA.D,CXXC
active site of PmDsbAC30S:PWATCDS. For panels C and D, the electron density is from 2F0 Fc FFT maps generated in Phenix (53) and contoured at 1.0 .
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mation. Binding of PWATCDS results in an average buried sur-
face area (i.e. surface that becomes inaccessible to solvent) of
955 12 Å or 9.0 0.1% of the total surface of PmDsbAC30S
(values are mean S.D. generated from the three molecules in
the asymmetric unit). This is similar in area to the EcDsbA
buried surface upon binding of the EcDsbB P2 loop (924 Å2)
(30). In both structures a major feature is the binding of an
aromatic residue in the hydrophobic groove. EcDsbB P2 loop
residue Phe101 forms a T-shaped 	-	 stacking interaction with
EcDsbA Phe174, whereas Trp2 of the PWATCDS peptide
forms a parallel 	-	 stacking interaction with PmDsbAC30S
Tyr173 and possible edge interactions with enzyme residues
Pro170 and Tyr40.
DISCUSSION
The increasing incidence of infections caused by multidrug-
resistant pathogens represents a serious global human health
issue. Indeed, the emergence of carbapenem-resistant Entero-
bacteriaceae threatens tomake common infections such as uri-
nary tract infections untreatable (69). Antibiotic resistance is
spreading rapidly and treatment options are becoming increas-
ingly limited. One possible approach to address the paucity of
FIGURE 4. Analysis of the interaction between peptide PWATCDS and PmDsbAC30S. A, superposition of the PWATCDS peptides from all three
protomerpeptide complexes in the asymmetric unit. Note the peptide includes an N-terminal acetyl and a C-terminal amide group. Carbon atoms are shown
in cyan, oxygens in red, nitrogens in blue, and sulfurs in yellow. B, location of the bound PWATCDS peptide on the surface of PmDsbAC30S (protomer A shown
in gray). Peptide residues are labeled and colored as for panel A. The yellow patch indicates the location of Ser30. C, electron densitymap of PWATCDS (chain F)
at the interface with PmDsbAC30S (chain B). The 2F0  Fc map was generated in Phenix (53) and is contoured at 1.0 . PmDsbAC30S residues forming the
binding site are labeled.D, interactions between the peptide (D–F, in cyan) and protein (chains A-C, in gray) are shown: hydrogen bonds are indicated as black
dashed lines; a circle highlights the stacking interaction between Trp2 and PmDsbAC30S Tyr173. E, superposition of the EcDsbB P2 periplasmic loop (PSPFATCD,
orange and black letters, PDB code 2ZUP) with PmDsbAC30S-PWATCDS (red letters, backbone in cyan). F, schematic representation of the interactions formed
between EcDsbB P2 loop binding to EcDsbA (top) in comparison to PWATCDS binding to PmDsbAC30S (bottom), showing the comparative shift in register.
Covalent bonds are shown as black lines, hydrogen bonds are indicated with red dashed lines, and hydrophobic interactions with black dotted lines.
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new antimicrobials in the developmental pipeline lies in the
generation of novel anti-virulence drugs (19, 70).
The Gram-negative DsbA/B system has been proposed as a
target for the development of novel anti-virulence drugs (17).
Targeting DsbA/B for development of inhibitors could be ben-
eficial in many ways. First, DsbA is not essential for bacterial
survival (27) although it plays an essential role in virulence (17).
Thus, inhibiting DsbA/B would not kill bacteria and this prop-
erty may reduce the selective pressure to develop resistance.
Second, structures of several DsbA homologues have been
solved (18, 28, 71), providing a framework for structure-based
drug design. Third, DsbA structures and properties are more
highly conserved than the structures and sequences of viru-
lence factors across pathogens (18). Therefore, inhibitors that
target one DsbA enzyme within a subclass are likely to block
DsbAs within the subclass offering the possibility of medium-
spectrum inhibitors (18).
Designing an inhibitor to block a protein-protein interface,
such as that of a DsbA, requires a comprehensive knowledge of
its binding interactions. Here we have used an innovative
approach to define the interaction surface of PmDsbA by
using knowledge from the low resolution crystal structure of
EcDsbA-EcDsbB.We characterized a peptide derived from the
sequence of DsbB, showed that it bound to PmDsbA and co-
crystallized it in a non-covalent complex with PmDsbAC30S.
This provides the first example of a high-resolution crystal
structure of a DsbA in complex with a non-covalently bound
peptide. Two previously published structures of DsbA in com-
plex with bound peptides include (i) EcDsbA bound covalently
with a substrate SigA-derived peptide; and (ii)Xyfella fastidiosa
DsbA also bound covalently with a peptide that co-crystallized
fortuitously.
P. mirabilis associated infections are often difficult to treat
due to its propensity to form biofilms (4). Two cell surface
organelles associated with P. mirabilis biofilm formation, man-
nose-resistant Proteus-like (MR/P) fimbriae (72) and flagella
(which mediate swarming) (4), require DsbA for their correct
assembly. Taken together, our data show that PmDsbA exhibits
redox, functional, and structural properties typical of the DsbA
class Ia enzymes (73), which extends to all DsbAs characterized
to date from Enterobacteriaceae (18).We expect that the struc-
tural details of the peptide binding mode and the interactions
observed will likely hold true for all of these enzymes. Specifi-
cally, the hydrophobic groove and the cis-Pro loop provide key
points of interaction that could be exploited further. The high-
resolution crystal structure of the non-covalent complex
between PmDsbAC30S and peptide may provide an important
platform for the development of peptidomimetic antivirulence
compounds targeting PmDsbA and by extension the DsbAs
from all Enterobacteriaceae.
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